Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform
Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.
Hikma Pharmaceuticals has announced that its venture capital arm, Hikma International Ventures and Development has participated in a $21.5 million series C round of financing for Propeller Health.
Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from chronic obstructive pulmonary disease (COPD), asthma and other respiratory diseases. This technology provides a novel combination of sensors, mobile applications, data analytics and personalised feedback, encouraging patient adherence to maintenance therapy. The Propeller Health device and technology has been used by patients with respiratory diseases in over 40 commercial programmes across the US, including major healthcare systems, payers and employers. The Propeller Health device is compatible with the majority of commonly used asthma and COPD inhaler devices including controller and reliever metered dose inhalers, and other inhaler devices (dry powder inhaler and soft mist inhaler). Propeller has partnered with several companies including Vectura Group to develop an add-on sensor for Vectura’s lever-operated multi-dose inhaler.
Hikma Ventures’ investment will be supporting the expansion of Propeller Health’s digitally guided therapy platform and modernise the management of respiratory disease. The market size for digital dose inhalers for asthma and COPD is expected to reach around $3.6 billion in 2024.
Lana Ghanem, Managing Director of Hikma Ventures, said: “Our investment in Propeller Health demonstrates our focus on identifying and investing in innovative, high potential digital health providers. We are very excited to be supporting the development of Propeller’s technology platform, which is enabling physicians, patients and providers to have advanced access to better quality data as well as improved medication adherence in the growing respiratory segment.”
David Van Sickle, CEO of Propeller Health, said, “Despite an abundance of effective treatments, the majority of people with chronic respiratory disease could be doing much better than they are. We’re excited to work with Hikma Ventures on our efforts to develop information-powered medicines that help people and their physicians achieve control of these conditions.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance